Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

BACKGROUND: Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires termination of treatment. However, we treated two patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Pulm Med
Hlavní autoři: Nitawaki, Tatsuya, Sakata, Yoshihiko, Kawamura, Kodai, Ichikado, Kazuya
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5718064/
https://ncbi.nlm.nih.gov/pubmed/29207989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0519-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky